Finance & Banking
BIO Investment & Growth Summit 2026
T
he new biotech CEO and investor conference from BIO, the BIO Investment & Growth Summit.
26Voices
11Underwriters
0Exhibitors
18On the bill · sessions
35Companies · in total
The Voices
Programmed at BIO, in alphabetical order.Abhijit Bhatia
Chief Operating Officer · Rakuten Medical
Amir Hefni
CEO · Resolution Therapeutics
Andy Lee
Co-founder & CBO · Vincere Biosciences Inc
Christer Rosén
Chairman & CEO · Jupiter Neurosciences, Inc.
Courtney Miller
Co-Founder, Myosin Therapeutics; Professor, Department of Molecular Medicine, Department of Neuroscience · UF Scripps Biomedical Research
Dan Salain
President & CEO · Recall Therapeutics
Gunner Hardy
Senior Associate · BOLD Longevity Growth Fund
Jayson Slotnik
Principal · Health Policy Strategies
Kelsey Kurth
Policy & Research, U.S. Policy and Government Affairs · Bristol Myers Squibb
Kerri-Ann Miller
Chief Financial Officer · Syncromune
Lucy To
EVP & Chief Financial Officer · SAB Bio
Mani Foroohar
Senior Managing Director, Genetic Medicines · Leerink Partners
Neil Warma
CEO · ProMIS Neurosciences
Peter Trepp
CEO/Founder · InnoPath Therapeutics
Phil Ball
Chief Business Officer · Tolerance Bio
Raghu Rao
President, Board Chair · Guidant BIotherapeutics
Raquel Cabo
Founder · Miami Biotech Collective
Rob Armstrong
Chief Executive Officer · Artax Biopharma
Samuel Reich
CEO · SAB Biotherapeutics
Steve Squinto
Chief Investment Officer · J.P. Morgan Life Science Private Capital
Viswa Colluru
Founder & CEO · Enveda
Wenzhi Tian
Chairman and CEO
— and 4 more, by name unsung —
Underwritten By
The houses behind the program. Tiers as disclosed.AvantorPremier
Blaise Group InternationalConference
CHUBBConference
Corporate TravelerConference
CytovancePremier
GATCConference
ScendeaConference
Southern Star ResearchConference
Syneos HealthPremier
The Money Channel NYCConference
The Programme
Selected from 18 sessions on the bill.- 01:30 PM – 02:15 PM
The High-Impact Investment Landscape in Immunology & Inflammation
Expansion in the target landscape, from TL1A and beyond, has accelerated progress in I&I drug development with multibillion-dollar M&A across the past two years attracting more fun…
- 01:30 PM – 02:30 PM
Spotlight on Innovation
The Innovation Stage offers a mix of programming showcasing biotech companies seeking breakthrough treatments and the University of Florida.
- 02:00 PM – 02:30 PM
Gator Dynamism: University of Florida’s Innovation in Biotech
- 02:30 PM – 03:15 PM
Investing in the Future of Cardiometabolic and Longevity Therapies: Differentiating Pipelines
GLP-1 analogs have rewritten treatment standards and changed patients’ expectations related to obesity, yet even more tantalizing is growing evidence they could hold the key to bro…
- 02:45 PM – 03:30 PM
Derisking Commercialization Plans to Attract Investment
As biotech funding dynamics evolve, investors are seeking capital models that reward commercial discipline and strategic partnership. Traditional venture pathways are giving way to…
- 03:45 PM – 04:30 PM
Balancing Global Opportunities and Trade Policy Risks
More than a third of U.S. licensing deals this year have involved assets sourced from China and investment is adjusting in response. As deal activity accelerates, regulatory scruti…
- 04:45 PM – 05:30 PM
Fireside Chat featuring Enveda’s CEO Viswa Colluru and UBS Analyst Mike Yee
In a capital-constrained environment, Enveda distinguished itself by securing high-quality funding at a rapid clip—closing a $150M Series D in late 2025 to achieve 'unicorn' status…
- 05:15 PM (ET)
Navigating the New Normal: Venture Investment Trends
HSBC’s mid-year report signaled the challenges that many small and mid-sized biotech companies have shared; first financings declined in Q2 of 2025 and entrepreneurs and companies …
- 09:00 AM – 09:45 AM
Bankers, Investors, and Biotech: What Would IPO Success in 2026 Require?
The pace of US biotech IPOs stalled for much of 2025 but reductions in interest rates corelate with an uptick in new offerings as investors reconsider the risks and returns from ne…
Intermission
Part the Second · For the Buyer
An audience of 35 companies, parsed from the program.
“35 companies in attendance.”
The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.
0All threespeak · spons · exh
11Sponsoringsponsor only
0Exhibitingexhibitor only
24Speakingspeaker only
85% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.
- C-suite1662%
- Founder / Owner312%
- VP-level14%
- Director / Head of28%
- Manager / Lead14%
- Other roles312%
Of 26 on the bill · classified by free-text title
- 01AvantorSp·P
- 02Blaise Group InternationalSp·C
- 03ChubbSp·C
- 04Corporate TravelerSp·C
- 05CytovanceSp·P
- 06GATCSp·C
- 07Johnson & Johnson Development CorporationSp·P
- 08ScendeaSp·C
- 09Southern Star ResearchSp·C
- 10Syneos HealthSp·P
- 11The Money Channel NYCSp·C
- 12Artax Biopharma1V
- 13BOLD Longevity Growth Fund1V
- 14Bristol Myers Squibb1V
conference7
64% of 11
premier4
36% of 11
- BIO International 2026June 22, 2026 · San Diego+ 4 shared